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Identity 
Other names: Fanconi pancytopenia 
Inheritance: autosomal recessive; frequency is about 
2.5/105 newborns. 
Clinics 
Note: Fanconi anaemia is a chromosome instability 
syndrome with progressive bone marrow failure and a 
increased risk of cancers. 
Phenotype and clinics 
- Growth retardation (70% of cases). 
- Skin abnormalities: hyperpigmentation and/or café au 
lait spots in 80%. 
- Squeletal malformations (60%), particularly radius 
axis defects (absent or hypoplastic thumb or radius...). 
- No immune deficiency (in contrast with most other 
chromosome instability syndromes). 
- Progressive bone marrow failure; mean age of onset 
of anemia: 8 yrs; diagnosis made before onset of 
haematologic manifestations in only 30%. 
- Other: renal anomalies, hypogonadism, mental 
impairment, heart defects, and perhaps diabetes 
mellitus, also occur in 10 to 30% of cases. 
Neoplastic risk 
- Myelodysplasia (MDS) and acute non lyphocytic 
leukaemia (ANLL): 10% of cases; i.e. a 15000 fold 
increased risk of MDS and ANLL has been evaluated 
in FA, and it has been assumed that 'it is reasonable to 
regard the Fanconi anemia genotype as 'preleukaemia''; 
mean age at diagnosis: 15 yrs. 
- Hepatocarcinoma (androgen-therapy induced) in 
10%; mean age at diagnosis: 16 yrs. 
- Other cancers in 2-5%: in particular squamous cell 
carcinoma. 
Treatment 
Androgens and steroids to improve haematopoietic 
functions; bone marrow transplantation prevents from 
terminal pancytopenia, and from ANLL as well. 
Prognosis 
Mean age at death: 16 years; most patients die from
marrow aplasia (haemorrhage, sepsis), and others from 
malignancies; MDS and ANLL in FA bear a very poor 
prognosis (median survival of about 6 mths); survival s 
also poor in the case of a squamous cell carcinoma. 
Cytogenetics 
Inborn condition 
- Spontaneous chromatid/chromosome breaks, 
triradials, quadriradials. 
- Hypersensitivity to the clastogenic effect of DNA 
cross-linking agents (increased rate of breaks and r dial 
figures); diepoxybutane, mitomycin C, or 
mechlorethamine hydrochlorid are used for diagnosis. 
Cancer cytogenetics 
- Various clonal anomalies are found in MDS or ANLL 
in Fanconi anaemia patients, such as the classical  
-5/del(5q), and -7/del(7q), found in 10 % of cases; 




- Slowing of the cell cycle (G2/M transition, with 
accumulating of cells in G2). 
- Impaired oxygen metabolism. 
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Genes involved and Proteins 
Complementation groups: 
4 well known complementation groups: group A (gene 
FA1 in 16q24, perhaps another gene 20q13), group B, 
group C (gene FACC in 9q22), group D (gene FAD in 
3p24 has sometimes been located in 11q23); a fifth 
group, group E, may, per se, be heterogenous; however, 
the different complementation groups display similar 
phenotypes, and genes may therefore be functionally 






Localisation: mostly cytoplasmic. 
Function: binds to the protein encoded by FACC (see 
below), the dimer being found in the cytoplasm and the 
nucleus. 
Homology: no known homology. 
Mutations 
Germinal: various nucleotide substitutions, deletions, 
or insertions. 
FACC 
Location: in 9q22 
Protein 
Expression: wide. 
Localisation: cytoplasmic when unbound. 
Function: peak expression during the G2/M transition; 
binds to cdc2 (mitotic cyclin-dependent kinase); 
probably involved in basic aspect(s) of the cell 
protection against DNA damages: role in the cell cycle 
regulation and/or in DNA repair and/or in the 
prevention of cellular apoptosis; binds to FAA, the 
protein encoded by FA1 (see above), the dimer being 
found in the cytoplasm and the nucleus. 
Homology: no known homology. 
Mutations 
Germinal: nucleotide substitutions. 
FAD 
Location: 3p24 
To be noted 
Clinical diagnosis may, in certain cases, be very 
difficult; cytogenetic ascertainment is then particularly 
useful; however, cytogenetic diagnosis may also, at 
times, be very uncertain; this is a great problem when 
bone marrow engraftment has been decided in a 
pancytopenic patient: if this patient has FA, bone 
marrow conditioning must be very mild, as FA cells are
very clastogen sensitive. 
FA patients (i.e. patients with defective alleles) may 
have, in a percentage of cells, a somatic reversion (by 
revert mutation towards wild-type gene); such a 
phenomenon is also known in Bloom syndrome, 
another chromosome instability syndrome. 
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